Combination chemotherapy directed at the components of nucleoside diphosphate reductase
- 31 December 1985
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 29 (1) , 111-127
- https://doi.org/10.1016/0163-7258(85)90019-1
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- The utility of combinations of drugs directed at specific sites of the same target enzyme — ribonucleotide reductase as the modelAdvances in Enzyme Regulation, 1985
- Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N′-aminoguanidine derivativesBiochemical Pharmacology, 1985
- Synergistic inhibition of human leukemia cell growth by deoxyguanosine and 1-β-d-arabinofuranosylcytosineBiochemical Pharmacology, 1984
- Role of ribonucleotide reductase in cell divisionPharmacology & Therapeutics, 1983
- Regulation of ribonucleotide reductase activity in mammalian cellsMolecular and Cellular Biochemistry, 1983
- Evidence that 5′-deoxy-5-fluorouridine may not be activated by the same mechanism as 5-fluorouracilBiochemical Pharmacology, 1982
- Effect of iron-chelating agents on inhibitors of ribonucleotide reductaseBiochemical Pharmacology, 1981
- Tight-binding inhibitors—IV. Inhibition of adenosine deaminases by various inhibitorsBiochemical Pharmacology, 1977
- Control of ribonucleotide reductase in mammalian cellsAdvances in Enzyme Regulation, 1976
- Ribonucleotide reductase as a site of inhibition of DNA synthesis by the dialdehyde derivatives of purine nucleosidesCancer Letters, 1975